sacituzumab tirumotecan
Coverage of sacituzumab tirumotecan in the Nexus archive.
- STAT+: EU and US advisers split over AstraZeneca breast cancer drug
EU and US regulatory advisers have diverged in their assessment of AstraZeneca's breast cancer drug, signaling potential approval challenges. The disagreement highlights different regulatory approaches between the two regions on this oncology treatment.
- STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
Merck and China-based Kelun-Biotech's drug sacituzumab tirumotecan demonstrated a 65% reduction in tumor progression risk in Phase 3 lung cancer trials. The study represents the first successful combination of an antibody-drug conjugate with PD-1 immunotherapy in advanced non-small cell lung cancer patients, with preliminary survival benefits observed.
- New drug approach offers hope for patients with recurrent aggressive cancers
A new treatment for endometrial cancer, sacituzumab tirumotecan, demonstrated strong potential in a Phase 3 clinical trial, meeting its primary endpoints of overall survival and progression-free survival. The trial involved 776 patients with advanced or recurrent endometrial cancer. The results show promise for addressing a critical unmet need for certain patients.